INBRX 105
Alternative Names: ES 101; INBRX-105; INBRX-105 - PDL1x41BB antibodyLatest Information Update: 30 Oct 2024
At a glance
- Originator Inhibrx
- Developer Elpiscience Biopharmaceuticals; Inhibrx
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hodgkin's disease; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 03 Oct 2024 Inhibrx Biosciences terminates a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) due to lack of meaningful efficacy signal (NCT03809624)
- 03 Oct 2024 Inhibrx Biosciences terminates a phase I trial in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) in USA (IV) due to lack of meaningful efficacy signal (NCT03809624)
- 30 May 2024 Inhibrx Biosciences acquires INBRX 105 from Inhibrx prior to May 2024